Latest News

Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.

In the VERIFY trial, rusfertide produced a clinical response in 77% of phlebotomy-dependent patients with polycythemia vera receiving standard-of-care therapy.

Pierre Gholam, MD, discussed how navigation, molecular profiling, and hub-and-spoke models can help liver tumor boards turn recommendations into care.

Neil Mehta, MD, and Laura Kulik, MD, discussed patient selection, washout timing, and posttransplant monitoring for immunotherapy before liver transplant.

Andrew Moon, MD, MPH, explained how liver function, biomarkers, and patient preferences should shape multidisciplinary treatment decisions in HCC.

Hashem B. El-Serag, MD, MPH, said HCC risk in MASLD centers on advanced fibrosis and cirrhosis, while extrahepatic cancers warrant routine screening.

More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.

Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.

Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.

Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.

Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.

The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.

Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.

Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.

Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.

Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.

In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.

In the phase 2 DALY 2-EU trial, zamto-cel prolonged median event-free survival vs R-GemOx in transplant-ineligible relapsed/refractory large B-cell lymphoma.

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.

Tyler J. Wilhite, MD, discussed coordinating with rheumatology, orthopedic surgery, and primary care when treating patients with osteoarthritis with low-dose radiation therapy.

Rutika Mehta, MD, MPH, discussed biomarker testing, PD-L1–low treatment, FLOT dosing, early referral, and ctDNA in gastroesophageal cancer.

Tyler J. Wilhite, MD, discussed scaling low-dose radiation therapy for osteoarthritis from 1 patient to nearly 20 centers and the referral work behind it.

Joshua Richter, MD, and Marco Davila, MD, PhD, discuss early evaluation, sequencing, referral partnerships, and access to CAR T-cell therapy in myeloma.

Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.

In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk of death in prostate cancer.

The FDA set a June 15, 2027, target action date for sacituzumab tirumotecan in endometrial cancer previously treated with platinum chemotherapy and immunotherapy.

Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.

Sunnie Kim, MD, outlined how she monitors for endocrine, renal, pulmonary, and other immune-related adverse events during adjuvant durvalumab.

Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.